PRESS RELEASE CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development LONDON “ 30 April 2024 -- CHARM Therapeutics (CHARM, The Company),...
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON “ 19 March 2024 -- CHARM Therapeutics (CHARM, The Company), a 3D deep-learning research company...
CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic Appointment
CHARM Therapeutics has received investment from NVIDIA’s venture investment arm, NVentures, for deep learning-enabled drug discovery research.
LONDON--(BUSINESS WIRE)--CHARM Therapeutics (“CHARM”), a 3D deep-learning biotechnology company discovering and developing transformational medicines, today announced an investment from NVentures, NVIDIA’s venture investment arm. The investment represents a major milestone for CHARM, enabling the company to further deliver on its research and development activities in the area of novel medicines for oncology.